Point72 Hong Kong’s BridgeBio Pharma BBIO Stock Holding History

Point72 Hong Kong’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39,227	Closed	-$390K	–	232
2022 Q3	$390K	Buy	+39,227	New	+$408K	0.01%	826
2022 Q2	–	Sell	-5,930	Closed	-$60K	–	1914
2022 Q1	$60K	Sell	5,930 -8,917	-60%	-$91.5K	﹤0.01%	1290
2021 Q4	$248K	Buy	+14,847	New	+$628K	0.01%	962
2020 Q4	–	Sell	-573	Closed	-$21K	–	1723
2020 Q3	$21K	Buy	+573	New	+$18K	﹤0.01%	858
2019 Q3	–	Sell	-9,437	Closed	-$255K	–	1007
2019 Q2	$255K	Buy	+9,437	New	+$257K	0.07%	267

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Hong Kong's BBIO Position: Q4 2022 in Review

Point72 Hong Kong sold out of BridgeBio Pharma (BBIO) in Q4 2022, closing a stake of 39,227 shares — an estimated $390K sold.

Point72 Hong Kong first reported a position in BBIO in Q2 2019 and held it in 5 quarters. The position peaked at $390K in Q3 2022. 179 funds tracked by Wall St. Rank hold BBIO as of Q4 2022.

Point72 Hong Kong reported no remaining BridgeBio Pharma position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 39,227 BridgeBio Pharma shares in Q4 2022, an estimated $390K.
Point72 Hong Kong first reported a position in BridgeBio Pharma in Q2 2019 and held it in 5 quarters.
Point72 Hong Kong's BridgeBio Pharma position peaked at $390K in Q3 2022.
179 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.